Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study

European Journal of Clinical Investigation

Volumn 46, Issue 5, 2016, Pages 481-490

  van Waateringe, Robert P ^a   Slagter, Sandra N ^a   van der Klauw, Melanie M ^a   van Vliet Ostaptchouk, Jana V ^a   Graaff, Reindert ^a   Paterson, Andrew D ^b   Lutgers, Helen L ^a   Wolffenbuttel, Bruce H R ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Advanced glycation end products; Aging; Cardiovascular disease; Determinants; Skin autofluorescence; Type 2 diabetes

Indexed keywords

ACYLTRANSFERASE; ADVANCED GLYCATION END PRODUCT; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ARYLAMINE ACETYLTRANSFERASE; BIOLOGICAL MARKER; COFFEE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; NAT2 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; BIOCHEMICAL ANALYSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COFFEE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; CUTANEOUS PARAMETERS; DIABETIC PATIENT; DIETARY INTAKE; DNA POLYMORPHISM; FEMALE; GENE LOCUS; GENOTYPE; HEALTH BEHAVIOR; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN; SKIN AUTOFLUORESCENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; AGE; AGED; CASE CONTROL STUDY; DIAGNOSTIC IMAGING; DRINKING BEHAVIOR; FLUORESCENCE IMAGING; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS;

ADULT; AGE FACTORS; AGED; ARYLAMINE N-ACETYLTRANSFERASE; BIOMARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; COFFEE; COHORT STUDIES; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DRINKING BEHAVIOR; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OPTICAL IMAGING; SKIN; SMOKING;

EID: 84963613874     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12627     Document Type: Article

References (46)

1. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993;91:2463-9.
2. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 1994;43:836-41.
3. Busch M, Franke S, Ruster C, Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010;40:742-55.
4. Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D et al. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011;32:763-77.
5. Monnier VM. Nonenzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol 1990;45:B105-11.
6. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999;55:389-99.
7. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000;28:1708-16.
8. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3687-93.
9. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006;29:2654-9.
10. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008;31:517-21.
11. Lutgers HL, Graaff R, de Vries R, Smit AJ, Dullaart RP. Carotid artery intima media thickness associates with skin autofluoresence in non-diabetic subjects without clinically manifest cardiovascular disease. Eur J Clin Invest 2010;40:812-17.
12. de Vos LC, Noordzij MJ, Mulder DJ, Smit AJ, Lutgers HL, Dullaart RP et al. Skin autofluorescence as a measure of advanced glycation end products deposition is elevated in peripheral artery disease. Arterioscler Thromb Vasc Biol 2013;33:131-8.
13. de Vos LC, Mulder DJ, Smit AJ, Dullaart RP, Kleefstra N, Lijfering WM et al. Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol 2014;34:933-8.
14. Koetsier M, Lutgers HL, de Jonge C, Links TP, Smit AJ, Graaff R. Reference values of skin autofluorescence. Diabetes Technol Ther 2010;12:399-403.
15. Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 1997;94:13915-20.
16. Eny KM, Orchard TJ, Grace MR, Maynard J, Grant DM, Costacou T et al. Caffeine Consumption Contributes to Skin Intrinsic Fluorescence in Type 1 Diabetes. Diabetes Technol Ther 2015;17:726-34.
17. Eny KM, Lutgers HL, Maynard J, Klein BE, Lee KE, Atzmon G et al. GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence. Diabetologia 2014;57:1623-34.
18. Stolk RP, Rosmalen JG, Postma DS, de Boer RA, Navis G, Slaets JP et al. Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol 2008;23:67-74.
19. Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, Vonk JM et al. Cohort Profile: LifeLines, a three-generation cohort study and biobank. Int J Epidemiol 2015;44:1172-80.
20. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-30.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
22. Jochemsen B, Mulder G, van DJ, Volmer M, Graaff R, Smit A. Relation between food and drinking habits, and skin autofluorescence and intima media thickness in subjects at high cardiovascular risk. J Food Nutr Res 2009;48:51-8.
23. Bekedam EK, Loots MJ, Schols HA, Van Boekel MA, Smit G. Roasting effects on formation mechanisms of coffee brew melanoidins. J Agric Food Chem 2008;56:7138-45.
24. Ding M, Bhupathiraju SN, Satija A, van Dam RM, Hu FB. Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 2014;129:643-59.
25. van Dam RM, Feskens EJ. Coffee consumption and risk of type 2 diabetes mellitus. Lancet 2002;360:1477-8.
26. Tuomilehto J, Hu G, Bidel S, Lindstrom J, Jousilahti P. Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women. JAMA 2004;291:1213-19.
27. Ding M, Satija A, Bhupathiraju SN, Hu Y, Sun Q, Han J et al. Association of coffee consumption with total and cause-specific mortality in three large prospective cohorts. Circulation 2015;132:2305-15.
28. Clifford MN. Chlorogenic acid and other cinnamates-nature, occurence, dietary burden, absorption and metabolism. J Sci Food Agric 2000;8:1033-43.
29. Arion WJ, Canfield WK, Ramos FC, Schindler PW, Burger HJ, Hemmerle H et al. Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase. Arch Biochem Biophys 1997;339:315-22.
30. Kim J, Jeong IH, Kim CS, Lee YM, Kim JM, Kim JS. Chlorogenic acid inhibits the formation of advanced glycation end products and associated protein cross-linking. Arch Pharm Res 2011;34:495-500.
31. Fernandez-Gomez B, Ullate M, Picariello G, Ferranti P, Mesa MD, del Castillo MD. New knowledge on the antiglycoxidative mechanism of chlorogenic acid. Food Funct 2015;6:2081-90.
32. Moon JK, Yoo HS, Shibamoto T. Role of roasting conditions in the level of chlorogenic acid content in coffee beans: correlation with coffee acidity. J Agric Food Chem 2009;57:5365-9.
33. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29-42.
34. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984;17:459-64.
35. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-27.
36. Karim MM, Jeon CW, Lee HS, Alam SM, Lee SH, Choi JH et al. Simultaneous determination of acetylsalicylic acid and caffeine in pharmaceutical formulation by first derivative synchronous fluorimetric method. J Fluoresc 2006;16:713-21.
37. Hoonhorst SJ, Lo Tam Loi AT, Hartman JE, Telenga ED, van den Berge M, Koenderman L et al. Advanced glycation end products in the skin are enhanced in COPD. Metabolism 2014;63:1149-56.
38. Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care 1999;22:1887-98.
39. Thorpe SR, Baynes JW. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 2003;25:275-81.
40. Makita Z, Yanagisawa K, Kuwajima S, Yoshioka N, Atsumi T, Hasunuma Y et al. Advanced glycation endproducts and diabetic nephropathy. J Diabetes Complications 1995;9:265-8.
41. Gerrits EG, Lutgers HL, Kleefstra N, Groenier KH, Smit AJ, Gans RO et al. Skin advanced glycation end product accumulation is poorly reflected by glycemic control in type 2 diabetic patients (ZODIAC-9). J Diabetes Sci Technol 2008;2:572-7.
42. Aroda VR, Conway BN, Fernandez SJ, Matter NI, Maynard JD, Orchard TJ et al. Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin a1c in type 1 diabetes. Diabetes Technol Ther 2013;15:117-23.
43. Sugisawa E, Miura J, Iwamoto Y, Uchigata Y. Skin autofluorescence reflects integration of past long-term glycemic control in patients with type 1 diabetes. Diabetes Care 2013;36:2339-45.
44. Wolffenbuttel BH, Giordano D, Founds HW, Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996;347:513-15.
45. Kilpatrick ES. The rise and fall of HbA(1c) as a risk marker for diabetes complications. Diabetologia 2012;55:2089-91.
46. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000;275:39027-31.